Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02501902 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT02501902 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 76 participants.
The verdict
NCT02501902, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD expansion cohort(s). Approximately 30-60 patients are expected to be enrolled in the overall study.
Interventions
- DRUG Nab-Paclitaxel
- DRUG Palbociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2015-11-23 |
| Est. Completion | 2018-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02501902
The ClinicalTrials.gov registry entry for NCT02501902 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nab-Paclitaxel is the first listed.
NCT02501902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02501902 about?
NCT02501902 is a clinical study titled "Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC". This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD expansion cohort(s). Approximately 30-60 patients are expected to be e...
What is the current status of trial NCT02501902?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2015-11-23. Estimated completion is 2018-12-27.
What interventions are being tested in trial NCT02501902?
The interventions under investigation include: Nab-Paclitaxel (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT02501902?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.